Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Facility-level variation in hepatosplenic T-cell lymphoma care: Comparative outcomes from academic and community cancer centers

Daniel Rosas, Leyla Bojanini, Supreet Kaur et al. Nov 03, 2025 pp. 3638-3638 10.1182/blood-2025-3638

Abstract Background Hepatosplenic T-cell lymphoma (HSTCL) is a rare, aggressive peripheral T-cell lymphoma subtype with...

Efficacy and safety of luspatercept in the treatment of anemia in allo-HSCT for patients with hematological diseases

Shi-Wei Jin, Mengmeng Pan, Weiping Zhang et al. Nov 03, 2025 pp. 2438-2438 10.1182/blood-2025-2438

Abstract Background: Persistent anemia affects up to 30% of long-term survivors after allogeneic hematopoietic stem-cell transplantation (al...

Rituximab for KSHV-associated multicentric castleman disease: A phase II safety/efficacy trial

Amon Chirwa, TARSIZIOUS CHIKAONDA, Marriam Mponda et al. Nov 03, 2025 pp. 1235-1235 10.1182/blood-2025-1235

Abstract Objectives: HIV-associated multicentric Castleman disease (MCD) has recently been recognized as an important emerging comorbidity i...

Uneven gains: Disparities in pneumonia-associated mortality among myeloid leukemia patients in the United States, 1999–2020 — a CDC wonder and joinpoint analysis

FNU Deeksha, Muhammad Umer, Sai Sushrutha Mudupula Vemula et al. Nov 03, 2025 pp. 6384-6384 10.1182/blood-2025-6384

Abstract Introduction Patients with myeloid leukemia are highly susceptible to infectious complications due to their imm...

Association of the easix score with survival and adverse outcomes in a large elderly hispanic cohort of patients with multiple myeloma.

Marco Ruiz, Sandra Sepulveda, Jorge Valdez et al. Nov 03, 2025 pp. 4001-4001 10.1182/blood-2025-4001

Abstract Background: Risk stratification in multiple myeloma (MM) is critical for guiding treatment decisions. The Endothelial Activation and...

Quality of life in multiple myeloma: A scoping review

Aoshuang Xu, Han Yan, Qun Li et al. Nov 03, 2025 pp. 2807-2807 10.1182/blood-2025-2807

Abstract Background With the increasing availability of novel therapies for multiple myeloma (MM), MM is transitioning i...

Glucose-6-phosphatase dehydrogenase [G6PD] serum level predicts acute monocytic leukemia differentiation.

Alexander Shkembi, Jonathan Andreadakis, Olivia Wilkins et al. Nov 03, 2025 pp. 6902-6902 10.1182/blood-2025-6902

Abstract Introduction: Acute Myeloid Leukemia [AML] leukemogenesis follows differentiation fate that resembles normal hematopoiesis, albeit...

Sickle cell disease and atrial fibrillation: A national perspective on catheter ablation utilization and comorbidities

Sangam Sangam, Rakendu Rajendran, Pedro Arias-Sanchez et al. Nov 03, 2025 pp. 6534-6534 10.1182/blood-2025-6534

Abstract Background: Patients with sickle cell disease (SCD) are at increased risk of atrial fibrillation (AF). Catheter ablation is a well-...

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes

Guillermo Garcia-Manero, Lalit Saini, Amer Zeidan et al. Nov 03, 2025 pp. 790-790 10.1182/blood-2025-790

Abstract Background: Parenteral DNA methyltransferase inhibitors (DNMTi) such as azacitidine and decitabine (DEC), including an attenuated 3...

Paroxysmal nocturnal hemoglobinuria: Transplant experience using post-transplant cyclophosphamide in a resource-limited setting

Bishesh Sharma Poudyal, Devendra Acharya, Bikram Karki et al. Nov 03, 2025 pp. 7732-7732 10.1182/blood-2025-7732

Abstract Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a chronic, debilitating clonal hematopoietic stem cell disorder characte...

Evaluating the safety and tolerability of switching from emicizumab to fitusiran prophylaxis in adult males with severe hemophilia A, with or without inhibitors: SWITCH study, a trial in progress

Guy Young, Chanchala Kaddi, Shariq Ali et al. Nov 03, 2025 pp. 3076-3076 10.1182/blood-2025-3076

Abstract Introduction As the treatment landscape of hemophilia non-factor therapies expands, there is a growing need to improve understandin...

Impact of asparaginase discontinuation on outcomes in pediatric B-cell precursor acute lymphoblastic leukemia: Post hoc analysis of the JCCG ALL-B12 Study

Hisashi Ishida, Yasuhiro Okamoto, Motohiro Kato et al. Nov 03, 2025 pp. 5119-5119 10.1182/blood-2025-5119

Abstract Background Asparaginase (Asp) is a key component in the treatment of children with acute lymphoblastic leukemia (ALL), particularly...

Estimated total cost of care and patient out-of-pocket cost savings with first-line fixed duration venetoclax + obinutuzumab compared with treat-to-progression BTKi regimens among Medicare-eligible patients with chronic lymphocytic leukemia in the United States following the Inflation Reduction Act.

Sophia Li, Katherine Rosettie, Beenish Manzoor et al. Nov 03, 2025 pp. 4400-4400 10.1182/blood-2025-4400

Abstract Background: In a recently published United States (US) population model of patients with previously untreated chronic lymphocytic l...

Management and long-term hematologic and neurologic outcomes of IgM-related neuropathy: A single center experience

Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos et al. Nov 03, 2025 pp. 2184-2184 10.1182/blood-2025-2184

Abstract Background: IgM-related neuropathy is associated with the presence of IgM monoclonal paraprotein [IgM monoclonal gammopathy of unde...

Prognostic relevance of mutational profile in secondary Acute Myeloid Leukemia patients treated with CPX-351.

Carola Riva, Paola Minetto, Giovanni Marconi et al. Nov 03, 2025 pp. 1623-1623 10.1182/blood-2025-1623

Abstract Introduction and aims Acute Myeloid Leukemia (AML) is a heterogeneous disease, driven by the serial acquisition of somatic mutation...

Development of a novel CAR-T cell therapy using a multimodal approach to target T cell lymphoma

Xiaojing Ong, Thu Ngoc Nguyen, Joshua Casan et al. Nov 03, 2025 pp. 4112-4112 10.1182/blood-2025-4112

Abstract INTRODUCTION Relapsed/refractory T cell lymphoma (TCL) patients (both peripheral and cutaneous TCL) are aggressive malignancies wit...

Preservation of gonadal function following chemotherapy protocols with acvd and acvd-BV in adults diagnosed with advanced-stage Hodgkin lymphoma: A single center experience.

Ahmed Alaskar, Mohammed Alharbi Nov 03, 2025 pp. 7144-7144 10.1182/blood-2025-7144

Authors: Maryam Almutairi 1234, Mohammed AlHarbi1234, Abdullah Alsaleh1234, Mohsen Alzahrani1234, Bader Alahmari1234, Hind Salama1234, Abdulrahman Alraizah1234, Ayman Ibrahim1234,...

Comparative risk of thrombosis in adults with primary immune thrombocytopenia treated with eltrombopag versus romiplostim: A target trial emulation in the french adult immune thrombocytopenia (FAITH) cohort

Jérémy Zordan, Yoann Zadro, Agnès Sommet et al. Nov 03, 2025 pp. 1251-1251 10.1182/blood-2025-1251

Abstract Background : Immune thrombocytopenia (ITP) is a rare autoimmune disease, leading to bleeding and paradoxically to thrombosis. Eltro...

Single-cell multiomics reveals candidate cis-regulatory elements in NPM1-mutant AML

Elliot Eton, Saravanan Ganesan, JangKeun Kim et al. Nov 03, 2025 pp. 5260-5260 10.1182/blood-2025-5260

Abstract Acute myeloid leukemia (AML) is driven by diverse genetic alterations in hematopoietic precursor cells and has a high rate of relap...

Delta opiod receptor signaling modulates myeloid suppression in Myelodysplastic Syndromes

Tiffany Razabdouski, KRIT Ritthipichai, Pingyan Cheng et al. Nov 03, 2025 pp. 3841-3841 10.1182/blood-2025-3841

Abstract Myelodysplastic syndromes (MDS) are diseases for which innate immunity has been clearly established to be critical in its pathogene...

The score settles it? maybe not: Navigating postpartum VTE prophylaxis

Jennifer McIntosh, Kristen Corrao, Faisal Shahjehan et al. Nov 03, 2025 pp. 1348-1348 10.1182/blood-2025-1348

Abstract Background: The risk of venous thromboembolism (VTE) increases during pregnancy and continues to rise throughout pregnancy with max...

Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival

Panagiotis Malandrakis, Ioannis Kostopoulos, Ioannis Ntanasis-Stathopoulos et al. Nov 03, 2025 pp. 2216-2216 10.1182/blood-2025-2216

Abstract Introduction Minimal residual disease (MRD) is a sensitive tool for evaluating treatment response in multiple m...

PPP1R15A as a therapeutic target to overcome chemoresistance in AML: An in vitro study

Christina Sotiropoulou, Christos Kontos, Anthi Bouchla et al. Nov 03, 2025 pp. 6799-6799 10.1182/blood-2025-6799

Abstract Introduction: Acute myeloid leukemia (AML) is often characterized by impaired DNA damage response (DDR), promoting chemoresistance...

Epigenetic silencing via SP140 and H3K27me3 restricts immunogenic viral antigen expression in EBV+ lymphomas

Isabella Kong, Herman Van Besien, Sarah Clark et al. Nov 03, 2025 pp. 326-326 10.1182/blood-2025-326

Abstract Epstein-Barr virus (EBV) infection is implicated in the pathogenesis of a significant subset of human lymphomas. EBV+ tumors exhibi...

Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study

Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfò et al. Nov 03, 2025 pp. 6287-6287 10.1182/blood-2025-6287

Abstract Background. Clinical trials have documented the efficacy of ibrutinib in combination with venetoclax in CLL. Indeed, Ibrutinib plus...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page